TY - JOUR
AU - Park, Dong-Guk
AB - Journal of the Korean Society of Editorial Coloproctology J Korean Soc Coloproctol 2011;27(3):103-104 pISSN 2093-7822 eISSN 2093-7830 DOI: 10.3393/jksc.2011.27.3.103 www.coloproctol.org Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas? Dong-Guk Park Department of Surgery, Dankook University School of Medicine, Cheonan, Korea See Article on Page 127-132 way [6]. Nonetheless, at the present time, mutation of KRAS is the only negative molecular marker to anti-EGFR mAbs treat- ment [2, 5]. Recently, a somatic mutation of the EGFR kinase Expression of epidermal growth factor receptor (EGFR) was domain was initially reported in lung cancer and later in colorec- found in 60-75% of colorectal carcinomas. Based on this, many tal carcinomas. In lung cancer, mutations in the EGFR gene studies have demonstrated the efficiency of monoclonal Abs are associated with a high response rate to EGFR tyrosine ki- (mAbs) in targeting the EGFR, such as cetuximab and panitu- nase inhibitors and are prognostic for a favorable outcome. mumab, in metastatic colorectal cancer (mCRC) patients. Ad- In this paper, the authors reported the incidence of the EGFR dition of cetuximab to irinotecan-based chemotherapy signifi - mutation in colorectal carcinomas as 22.41%. The incidence cantly improved the response 
TI - Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
JF - Journal of the Korean Society of Coloproctology
DO - 10.3393/jksc.2011.27.3.103
DA - 2011-06-30
UR - https://www.deepdyve.com/lp/pubmed-central/are-mutations-of-the-egfr-gene-promising-predictive-markers-for-anti-thGoLa6t6J
SP - 103
EP - 104
VL - 27
IS - 3
DP - DeepDyve
ER -